Clinical trials: Precancerous Conditions
Barrett's Esophagus
Barrett's Esophagus - 315 - 3 Way Cross-Over
This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.
- Trial name
- NCT00637559
- Testing
- Esomeprazole Magnesium
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Actinic Keratoses
ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis
The objective of this non-interventional study (NIS) is to gain comprehensive insights into the practicability of ADL-PDT with Metvix® in patients with actinic keratoses under real-world conditions.
- Trial name
- NCT05725213
- Testing
- Metvix® 160 mg/g Creme
- Where
- Germany
- Volunteers
- 224 people
- Sponsor
- Galderma Laboratorium GmbH
Breast Cancer, Preneoplastic Conditions, BRCA
A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old
The purpose of this study is to measure the performance of the ForeCYTE Breast Aspirator for the collection and processing of Nipple Aspirate Fluid (NAF) specimens for cytology.
- Trial name
- NCT02539615
- Testing
- ForeCYTE Breast Aspirator
- Where
- 2 sites in Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
Actinic Keratosis
Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
This is a Phase 2 clinical study in patients with actinic keratosis involving daily application of 1 of 2 strengths of VDA-1102 topical ointment for approximately 12 weeks (84 days).
- Trial name
- Phase2b (NCT03538951)
- Testing
- 10% VDA-1102, 20% VDA-1102
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Vidac Pharma
Actinic Keratoses
Treatment of Actinic Keratosis With 5% KOH Solution
This is a prospective single-arm multicenter medical device study to investigate the clinical efficacy and safety of the treatment of actinic keratosis with a 5% potassium hydroxide solution.
- Trial name
- TAKKOH (NCT04024579)
- Where
- 6 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Infectopharm Arzneimittel GmbH
Actinic Keratosis
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
The purpose of this study is to determine if Levulan photodynamic therapy (PDT) is safe and effective in the treatment of actinic keratoses (AK) on the face, following treatment with liquid nitrogen cryotherapy.
- Trial name
- NCT02239679
- Testing
- Aminolevulinic Acid, Topical Solution Vehicle, BLU-U
- Where
- 8 sites in United States
- Volunteers
- 166 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Mouth Diseases
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective…
- Trial name
- NCT05853783
- Testing
- STRATICYTE™ Test
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Proteocyte Diagnostics Inc.
Barrett's Esophagus, Esophageal Cancer
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
The purpose of this study is to evaluate a cryoablation technique used to ablate human esophageal mucosa.
- Trial name
- NCT01293448
- Testing
- Cryoballoon Ablation
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 21 people
- Sponsor
- Pentax Medical
Keratosis
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands.
- Trial name
- NCT00116649
- Testing
- imiquimod cream
- Where
- 32 sites in United States
- Volunteers
- 551 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Barrett Syndrome, Barrett's Syndrome
CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
This study focuses on demonstrating the value of probe-based Confocal Laser Endomicroscopy (pCLE) in guiding endoscopic therapeutic procedures in Barrett's Esophagus (BE).
- Conditions
- Barrett Syndrome, Barrett's Syndrome, Barrett's Esophagus, Barrett Esophagus
- Trial name
- CLEAN-MARGIN (NCT01032044)
- Testing
- Standard endoscopic evaluation, pCLE guided evaluation
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 164 people
- Sponsor
- Mauna Kea Technologies
Actinic Keratosis
A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)
The open label study is designed to assess the safety and efficacy of 0.05% PEP005 Gel when applied to an area of skin containing 4-8 AK lesions on non-head locations.
- Trial name
- NCT00917306
- Testing
- PEP005 Gel
- Where
- 11 sites in United States, Australia
- Volunteers
- 102 people
- Sponsor
- Peplin
Actinic Keratosis
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream or Solaraze® 3% gel on the face or the scalp.
- Trial name
- LEIDA (NCT00777127)
- Testing
- Imiquimod, Diclofenac
- Where
- 26 sites in Austria, France and 1 more
- Volunteers
- 258 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Keratosis
1-Year Follow up to the 1473-IMIQ Study
This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study.
- Trial name
- NCT00114023
- Testing
- Imiquimod 5% cream
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Graceway Pharmaceuticals, LLC
Myelofibrosis, Leukemia, Myelocytic, Acute
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Phase 1 Part: This was an open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients who had previously been treated for Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms.
- Conditions
- Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02158858
- Testing
- Pelabresib, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 336 people
- Sponsor
- Constellation Pharmaceuticals
Barrett Esophagus, Esophageal Adenocarcinoma
Lucid Registry Study
This is a multicenter, prospective, observational study designed to capture a limited set of data consisting of diagnostic test results and clinical management information on subjects who undergo EC/EG to assess for the presence…
- Conditions
- Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
- Trial name
- Lucid Registry (NCT05965999)
- Testing
- EsoCheck®, EsoGuard®
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Lucid Diagnostics, Inc.
Actinic Keratosis
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.
- Trial name
- NCT02632110
- Testing
- ALA, Topical Solution Vehicle, IBL 10 mW
- Where
- 8 sites in United States
- Volunteers
- 137 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Actinic Keratosis
Trial to Investigate GZ21T in Healthy Volunteers
This is a double-blind, randomised, placebo-controlled trial designed to evaluate safety, tolerability, and pharmacokinetics (PK) after topical administration of single ascending doses of GZ21T in healthy volunteers.
- Trial name
- NCT06888362
- Testing
- GZ21T
- Where
- Sweden
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Actinic Keratosis
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
- Trial name
- NCT02838628
- Testing
- 50 mg of KX2-391 Ointment 1%
- Where
- 16 sites in United States
- Volunteers
- 168 people
- Sponsor
- Almirall, S.A.
Cervical Intraepithelial Neoplasia, Low-Grade Squamous Intraepithelial Lesions
Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)
This trial will study the effectiveness of photodynamic therapy with aminolaevulinic acid for the treatment of patients with HPV+ low grade cervical intraepithelial neoplasia (LSIL;CIN1).
- Conditions
- Cervical Intraepithelial Neoplasia, Low-Grade Squamous Intraepithelial Lesions, Papillomavirus Infections
- Trial name
- NCT02631863
- Testing
- Aminolaevulinic acid
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Cervical Intraepithelial Neoplasia
A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia
This is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in participants with cervical squamous intraepithelial lesions. This study is divided into 2 parts - Part A and Part B.
- Trial name
- NCT05502367
- Testing
- ABI-2280 Vaginal Tablet/Insert
- Where
- 7 sites in Australia, Peru and 1 more
- Volunteers
- 44 people
- Sponsor
- Antiva Biosciences